Anavex Life Sciences Corp (AVXL)

[MayoMobile]

Funny, I discussed this topic to some degree with Dr. Macfarlane. Discussed the differences between U.S. and Australian healthcare coverage and he mentioned that the TGA is extremely hesitant to approve the antibody drugs due to their enormous cost. He said there isn’t enough efficacy for the TGA/Australian government to fully buy in.

This is one of the reasons I hit on lower cost in my CTAD summary. While exact price is unknown, I have hypothesized that drug will cost NO MORE than $10,000 annually per patient. That is an immense cost savings over Aduhelm (and most likely future Lecanemab sales). Like I said, TGA has a lot to gain.